PCSK9 LNA Antisense Oligonucleotides Induce Sustained Reduction of LDL Cholesterol in Nonhuman Primates

Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a therapeutic target for the reduction of low-density lipoprotein cholesterol (LDL-C). PCSK9 increases the degradation of the LDL receptor, resulting in high LDL-C in individuals with high PCSK9 activity. Here, we show that two loc...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Lindholm, Marie W, Elmén, Joacim, Fisker, Niels, Hansen, Henrik F, Persson, Robert, Møller, Marianne R, Rosenbohm, Christoph, Ørum, Henrik, Straarup, Ellen M, Koch, Troels
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2012
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3277239/
https://ncbi.nlm.nih.gov/pubmed/22108858
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/mt.2011.260
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars